Chemical Property of Vorapaxar sulfate
Chemical Property:
- PSA：160.50000
- LogP:6.44840
- Hydrogen Bond Donor Count:3
- Hydrogen Bond Acceptor Count:10
- Rotatable Bond Count:6
- Exact Mass:590.20981541
- Heavy Atom Count:41
- Complexity:902
- Purity/Quality:
-
99% *data from raw suppliers
VorapaxarSulfate *data from reagent suppliers
Safty Information:
- Pictogram(s):
- Hazard Codes:
- MSDS Files:
-
SDS file from LookChem
Useful:
- Canonical SMILES:CCOC(=O)NC1CCC2C(C1)CC3C(C2C=CC4=NC=C(C=C4)C5=CC(=CC=C5)F)C(OC3=O)C.OS(=O)(=O)O
- Isomeric SMILES:CCOC(=O)N[C@@H]1CC[C@@H]2[C@@H](C1)C[C@@H]3[C@H]([C@H]2/C=C/C4=NC=C(C=C4)C5=CC(=CC=C5)F)[C@H](OC3=O)C.OS(=O)(=O)O
- Recent ClinicalTrials:Vorapaxar Study for Maturation of AV Fistulae for Hemodialysis Access
- Recent EU Clinical Trials:Vorapaxar in the human endotoxemia model
-
Description
Merck Sharp & Dohme successfully obtained approval in the EU
in 2014 for vorapaxar sulfate, marketed as Zontivity?. The drug is a
first-in-class thrombin receptor (also referred to as a protease-activated
or PAR-1) antagonist which, when used in conjunction with
antiplatelet therapy, has been shown to reduce the chance of
myocardial infarction and stroke, particularly in patients with a
history of cardiac events. Antagonism of PAR-1 allows for
thrombin-mediated fibrin deposition while blocking thrombinmediated
platelet activation.
-
Uses
SCH-530348 is a novel antiplatelet agent undergoing development by Schering-Plough Corp for the treatment and prevention of atherothrombosis.
acute coronary syndrome (unstable angina/non-ST segment elevation myocardial infarction) and secondary prevention of cardiovascular events in high-risk patients.
